Durazzo A, Lucarini M, Souto E, Cicala C, Caiazzo E, Izzo A, Novellino E, Santini A (2019) Polyphenols: a concise overview on the chemistry, occurrence, and human health
Victoza has a longer clinical history approved in 2010 vs Ozempic in 2017 with well-established 15-year safety data from the LEADER cardiovascular outcomes trial
BENEFITS Promotes fatty acid metabolism in the liver Promotes metabolic flexibility and homeostasis Helps regulate mitochondrial energy Protects against age and diet dependent insulin resistance and obesity Helps with weight loss Promotes resistance to metabolic stress Improves exercise capacity Helps prevent osteoporosis Improves glucose regulation Promotes cell differentiation to form osteoblasts According to study results, this treatment patients run significantly longer and further than untreated patients
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
767, pubmed.ncbi.nlm.nih.gov/39941438/,
My top 3 non-negotiables I take every single morning
,aspect=ignore)
